A cloth-covered box (a) that closes with two snaps at the front and is lined with velvet contains the samples; inside is a moulded plastic tray (b) with five bottles in it: Milontin®, a rectangular glass bottle (c) with threaded metal cap (d), full of capsules with cotton stuffed in the neck; Dilan…
A cloth-covered box (a) that closes with two snaps at the front and is lined with velvet contains the samples; inside is a moulded plastic tray (b) with five bottles in it: Milontin®, a rectangular glass bottle (c) with threaded metal cap (d), full of capsules with cotton stuffed in the neck; Dilantin® 0.03 gram, a rectangular glass bottle (e) with threaded metal cap (f), full of capsules with cotton stuffed in the neck; Zarontin®, a cylindrical glass bottle (g) with a threaded metal cap (h), full of capsules; Dilantin® 0.4 gram, a rectangular glass bottle (i) with threaded metal cap (j), full of capsules, with cotton stuffed in the neck; and Celontin®, a rectangular glass bottle (k) with a threaded metal cap (l), full of capsules, with cotton stuffed in the neck; also in the box is a 30-page booklet with product information (m); pages 5, 13, 17 and 21 have tabs at the top, making it possible to skip directly to the information on the product that begins on that page.
Number Of Parts
13
Part Names
a - box - Size: Length 31.2 cm x Width 17.2 cm x Depth 7.1 cm
b - tray - Size: Length 29.2 cm x Width 15.1 cm x Depth 4.8 cm
c - Milontin bottle - Size: Length 10.4 cm x Width 4.1 cm x Depth 6.2 cm
d - cap - Size: Depth 1.0 cm x Diam. 3.9 cm
e - Dilantin 0.03 bottle - Size: Length 8.0 cm x Width 4.4 cm x Depth 3.1 cm
f - cap - Size: Depth 1.0 cm x Diam. 3.0 cm
g - Zarontin bottle - Size: Length 10.0 cm x Diam. 5.0 cm
h - cap - Size: Depth 1.0 cm x Diam. 3.9 cm
i - Dilantin 0.1 bottle - Size: Length 8.0 cm x Width 4.6 cm x Depth 3.1 cm
j - cap - Size: Depth 1.0 cm x Diam. 3.4 cm
k - Celontin bottle - Size: Length 9.7 cm x Width 4.1 cm x Depth 5.1 cm
l - cap - Size: Depth 1.0 cm x Diam. 3.4 cm
m - booklet - Size: Length 12.7 cm x Width 8.4 cm x Depth 0.3 cm
(c) Front: "Pr 100 No. 393 // KAPSEALS® // MILONTIN® // PHENSUXIMIDE // CAPSULES N.F. // 0.5 GRAM // The orange capsule with contrast- // ing orange band is a Parke-Davis // trademark. // Parke, Davis & Company, Ltd. // Brockville, Ontario // PARKE-DAVIS // Stock 15-393-4 [printed] Lot AE129 [stamped]"; right side: "Anticonvulsant // USUAL DOSE – 1 or 2 capsules two or three // times daily. // Before instituting treatment, read medical // literature, available to physicians on re- // quest, for indications and directions. // Keep Bottle Securely closed in a Cool, // Dry Place. // DISPENSE IN MOISTURE PROOF CONTAINER"; left side: right side repeated in French; bottom: "160 // 9 // 4 [embossed]"; (e) front: "Pr 100 No. 365 // KAPSEALS® // DILANTIN® // DIPHENYLHYDANTOIN // SODIUM CAPSULEA // U.S.P. // 0.03 GRAM // (1½ gr.) // Parke, Davis & Company, Ltd. // Brockville, Ontario // PARKE-DAVIS // Stock 15-365-4 [printed] // Lot AB163 [stamped]"; right side: "Anticonvulsant // DOSE – Children under 6 years, 1 // capsule three or four times daily or // as directed by the physician. // The white capsule with pink band is a // Parke-Davis trademark. // DISPENSE IN MOISTURE PROOF // CONTAINER"; left side: "Antiépileptique // POSOLOGIE – Enfants 6 ans et moins, // 1 capsule trois ou quatre fois par jour // ou selon l'ordonnance du médecin. // N'UTILISER QUE DES // CONTENANTS HYDROFUGES"; bottom: "L // 50 8 // 7 [embossed]"; (g) front: "Pr 100 S.G.C. No. 237 // ZARONTIN® // ETHOSUXIMIDE // CAPSULES B.P. // S.G. Capsules // 0.25 GRAM // Parke, Davis & Company, Ltd. // Brockville, Ontario // PARKE-DAVIS // Stock 7-237-4 [printed] // Lot AF148 [stamped]"; right side: "Anticonvulsant // USUAL DOSE–Initially, 1 or 2 capsules, // increased gradually, as required, up to 8 // capsules daily. // Before instituting treatment, read medical // literature, available to physicians on request, // for indications and directions. // Keep Bottle Securely Closed in a // Cool, Dry Place. // DISPENSE IN MOISTURE PROOF CONTAINER [printed]"; left side: right side repeated in French; bottom: "9 // 120 18 // 4765 [embossed]"; (i) front: "Pr 100 No. 362 // KAPSEALS® // DILANTIN® // DIPHENYLHYDANTOIN // SODIUM CAPSULES // U.S.P. // 0.1 GRAM // (1½ gr.) // The white capsule with orange // band is a Parke-Davis trademark. // PARKE-DAVIS // Stock 15-362-4 [printed] // L [encircled] Z 216 F [stamped]"; left side: "Anticonvulsant // DOSE–Adults and children 6 years or // older, 1 capsule three or four times // daily or as directed by the physician. // DISPENSE IN MOISTURE PROOF // CONTAINER // Parke, Davis & Company, Ltd. // BROCKVILLE, ONTARIO"; left side: "right side repeated in French except last two lines; bottom: "60 // L 9 // 10 [embossed]"; (k) front: "Pr 100 No. 525 // KAPSEALS® // CELONTIN® // METHSUXIMIDE // CAPSULES N.F. // 0.3 GRAM // The yellow capsule with orange band // is a Parke-Davis trademark. [printed] // Lot Z 114 L [stamped] // PARKE-DAVIS Stock 15-525-4 [printed]"; right side: "Anticonvulsant // USUAL DOSE– 1 to 4 capsules daily. // Before instituting treatment, read med- // ical literature, available to physicians on // request, for indications and directions. // Keep Bottle Securely Closed In a // Cool, Dry Place. // DISPENSE IN MOISTURE PROOF CONTAINER // Parke, Davis & Company, Ltd. // Brockville, Ontario [printed]"; left side: right side repeated in French, except for last two lines; bottom: "100 3 // 2 [embossed]"; (m) cover: "PARKE-DAVIS // ANTIEPILEPTIC // PRODUCTS // for grand mal and // psychomotor seizures // DILANTIN ® // DILANTIN® // with PHENOBARBITAL // PHELANTIN® // ZARONTIN® // MILONTIN® // for petit mal triad // for petit mal and psychomotor seizures // CELONTIN® // DILANTIN STERI-VIAL® // for status epilepticus and control // of seizures during neurosurgery"; inside cover: "EPILEPSY – A HANDICAP ON THE WANE // [text follows]"; page 1: "PARKE-DAVIS ROLE IN THE TREATMENT OF EPILEPSY // [text follows] // 1"; page 2: "[text continues from page 1] // 2"; page 3: "text continues from page 2] // 3"; page 4: "DILANTIN® // [text follows] // INDICATIONS: // [text follows] // CLINICAL DISCUSSION: // [text follows] // 4"; page 5: "DILANTIN® [on tab] // [text continued from page 4] // 5"; page 6: "[text continues from page 5 // FORMS AVAILABLE: // [text follows] // 6"; page 7: "[text continues from page 6] // 7"; page 8: "[text continues from page 7] // DOSAGE AND ADMINISTRATION (DILANTIN): // [text follows] // ORAL ADMINISTRATION: // [text follows] // 8"; page 9: "[text continues from page 8] // PARENTERAL ADMINISTRATION: // [text follows] // 9"; page 10: "[text continues from page 9] // PRECAUTIONS AND CONTRAINDICATIONS (DILANTIN): // [text follows] // 10"; page 11: "[text continues from page 10] // SIDE EFFECTS (DILANTIN): // [text follows] // 11"; page 12: "MILONTIN® // [text follows] // INDICATIONS: // [text follows] // CLINICAL DISCUSSION: // [text follows] // 12"; page 13: "MILONTIN® [on tab] // [text continued from page 12] // 13"; page 14: "FORMS AVAILABLE: // [text follows] // DOSAGE AND ADMINISTRATION (MILONTIN): // [text follows] // PRECAUTIONS (MILONTIN): // [text follows] // Detailed information available on request. // PARKE-DAVIS // 15"; page 16: "CELONTIN® // [text follows] // INDICATIONS: // [text follows] // CLINICAL DISCUSSION: // [text follows] // 16"; page 17: "CELONTIN® [on tab] // [text continued from page 16] // 17"; page 18: "[text continued from page 17] // 18"; page 19: "FORMS AVAILABLE: // [text follows] // DOSAGE AND ADMINISTRATION (CELONTIN): // [text follows] // PRECAUTIONS (CELONTIN): // [text follows] // 19"; page 20: "[text continues from page 19] // SIDE EFFECTS (CELONTIN): // [text follows] // Detailed information available on request. // PARKE-DAVIS // 20"; page 21: "ZARONTIN® [on tab] // ZARONTIN // [text follows] // INDICATIONS: // [text follows] // CLINICAL DISCUSSION: // [text follows] // 21"; page 22: "text continues from page 21] // 22"; page 23: "[text continues from page 22] // 23"; page 24: "[text continues from page 23] // 24"; page 25: "FORMS AVAILABLE: // [text follows] // DOSAGE AND ADMINISTRATION (ZARONTIN): // [text follows] // PRECAUTIONS (ZARONTIN): // [text follows] // 25"; page 26: "[text continues from page 25] // SIDE EFFECTS (ZARONTIN): // [text follows] // Detailed information available on request. // PARKE-DAVIS // 26"; page 27: "REFERENCES // [text follows] // 27"; page 28 "[text continues from page 27 // 28"; back cover: "PARKE-DAVIS // PARKE, DAVIS & COMPANY, LTD. // Montreal . Brockville . Toronto // Winnipeg . Edmonton . Vancouver // PD-6944-C (10-69) Printed in Canada"; all marks in booklet (m) are printed.
Permanent Location
Storage Room 0010
0010-A6-4
Unit Of Measure
centimeters
Condition Remarks
Box is dusty; fabric worn through on corners and peeling on back; paint scratched on snaps; velvet inside is crushed flat where it pressed against tray or bottles; tray is dusty and cracked in numerous places and some small pieces are broken off completely; glass bottles are dusty; scratched paint on all the caps, but no corrosion; booklet is scuffed and tabs are creased; ink on front cover is fading.